"When you come to see us, we take the time to really see you Ñ to understand who you are, and what matters to you most. These insights allow us to deliver truly patient-centered primary care, specialty care, and urgent care at every stage of life. Your primary care provider takes the lead and coordinates your care across our entire network of nurses, specialists, and care managers Ñ all working in sync to fit your health needs."

During the past decade, HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway conducted 100 clinical trials. In the 10-year time frame, 100 clinical trials started and 58 clinical trials were completed, i.e. on average, 58% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 48 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" #1 sponsor was "National Cancer Institute (NCI)" with 70 trials, followed by "SWOG Cancer Research Network" with 27 trials sponsored, "Alliance for Clinical Trials in Oncology" with 21 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 11 trials sponsored and "NRG Oncology" with 11 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" #1 collaborator was "National Cancer Institute (NCI)" with 65 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator and "Bayer" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" are "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Recurrent Lung Non-Small Cell Carcinoma" (5 trials), "Stage IIIA Breast Cancer" (5 trials) and "Stage IV Cutaneous Melanoma AJCC v6 and v7" (5 trials). Many other conditions were trialed in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" in a lesser frequency.

Most popular intervention types in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" are "Drug" (109 trials), "Other" (91 trials), "Biological" (57 trials), "Procedure" (35 trials) and "Radiation" (17 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (49 trials), "Quality-of-Life Assessment" (31 trials), "Computed Tomography" (22 trials), "Biospecimen Collection" (21 trials) and "Nivolumab" (19 trials). Other intervention names were less common.

The vast majority of trials in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway" are 116 trials for "All" genders, 17 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway". undefined are not yet recruiting, 28 are recruiting, 72 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, 2 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, 3 "Phase 1" clinical trials were conducted, 70 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".